• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CFO & COO Connealy Pamela Ann

    4/2/25 8:56:28 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYXS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Connealy Pamela Ann

    (Last) (First) (Middle)
    C/O PYXIS ONCOLOGY, INC.
    321 HARRISON AVENUE, 11TH FL. SUITE 1

    (Street)
    BOSTON MA 02118

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Pyxis Oncology, Inc. [ PYXS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CFO & COO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/31/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $0.98 03/31/2025 A 414,163 (1) 03/31/2035 Common Stock 414,163 $0.98 414,163 D
    Explanation of Responses:
    1. The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31, 2025 and the remainder vesting in 36 equal monthly installments thereafter subject to the reporting person's continued emmployment through the applicable vesting date.
    /s/ Pamela Connealy 04/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PYXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PYXS

    DatePrice TargetRatingAnalyst
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    1/23/2024$12.00Outperform
    Leerink Partners
    9/5/2023$7.00Outperform
    RBC Capital Mkts
    11/2/2021$16.00Neutral
    B of A Securities
    More analyst ratings

    $PYXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

      6/10/24 7:30:00 AM ET
      $PYXS
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

      BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. "We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "Santhosh's guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical devel

      3/13/24 8:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director

      Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite and will bring clinical, strategic and financial leadership to biotech's board 1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.

      12/19/23 9:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pyxis Oncology Inc.

      10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:41:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:35:33 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pyxis Oncology Inc.

      SCHEDULE 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      5/6/25 4:17:33 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      11/27/24 5:09:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connealy Pamela Ann bought $14,960 worth of shares (8,000 units at $1.87), increasing direct ownership by 0.99% to 818,532 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/28/23 4:32:03 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wadhane Jitendra bought $4,675 worth of shares (2,500 units at $1.87), increasing direct ownership by 1% to 226,937 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/27/23 6:37:45 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President ,CEO & CMO Sullivan Lara

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:06:50 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Metzger Michael A

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:05:43 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Chief Accounting Officer Wadhane Jitendra

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:04:17 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Financials

    Live finance-specific insights

    See more
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

      - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20

      11/12/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

      - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected

      8/14/24 4:05:00 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

      PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradom

      5/14/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/12/24 11:53:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/6/24 4:36:24 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Pyxis Oncology Inc. (Amendment)

      SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      4/3/24 5:10:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pyxis Oncology downgraded by William Blair

      William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform

      11/21/24 7:55:42 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Pyxis Oncology with a new price target

      Stephens initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $13.00

      11/8/24 8:24:38 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Pyxis Oncology with a new price target

      Stifel initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $10.00

      8/8/24 6:48:55 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

      - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting mul

      5/15/25 7:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology to Participate in Two Upcoming Investor Conferences

      BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ETJefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET A live webcast and replay of the fireside chats will be available on th

      5/14/25 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

      Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's uniqu

      4/25/25 1:17:47 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care